Nigeria’s pharmaceutical sector has emerged as one of the strongest performers on the stock market in 2025, and Fidson Healthcare and May & Baker are driving the surge.
By September 16, Fidson’s shares had climbed 117% year-to-date, while May & Baker advanced 86.2%.
Meanwhile, as the wider market struggles with high inflation, currency volatility, and uneven corporate results, investors are turning to healthcare stocks for growth and stability.
In sharp contrast, industrials, real estate, and consumer goods companies continue to see their margins erode under rising input costs and foreign exchange pressures.
Earnings Power Growth
Fidson and May & Baker seized the opportunity by capitalising on resilient domestic demand and delivering strong earnings, which strengthened their leadership in the equity market.
In the first half of 2025, Fidson nearly quadrupled its profit after tax to ₦6.02 billion, while May & Baker lifted its profit by 150% to ₦876.6 million.
Moreover, both companies increased revenue, improved operational efficiency, and reduced foreign exchange losses compared with 2024, which helped them protect margins despite inflationary headwinds.
Risks And Resilience
However, challenges remain.
Both firms reported negative operating cash flows because trade receivables and prepayments grew sharply.
Read Also: China-Nigeria Partnership Ushers In Local Insulin Manufacturing
At the same time, Fidson doubled its borrowings, while May & Baker raised its debt by 28%.
Consequently, finance costs jumped, with May & Baker recording a 77% rise.
Even so, investors continue to show confidence.
They expect robust domestic demand and government incentives for local manufacturing to sustain growth.
Furthermore, Fidson’s product expansion and distribution reach, along with May & Baker’s expanding market presence, reinforce optimism.
Looking ahead, as healthcare consumption rises and local production scales up, the pharmaceutical sector is set to remain a bright spot in Nigeria’s equity market in 2025.
